Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States
Market Cap
416.6M
52 Wk Range
$2.71 - $6.42
Previous Close
$4.05
Open
$4.03
Volume
641,505
Day Range
$3.98 - $4.08
Enterprise Value
268.4M
Cash
156.3M
Avg Qtr Burn
-44.03M
Insider Ownership
1.15%
Institutional Own.
93.41%
Qtr Updated
06/30/26
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia | BLA Submission |